Interestingly, ALK-rearranged NSCLC tumors exhibit a high EMT phenotype frequency with decreased E-cadherin and increased vimentin expression compared to NSCLC tumors with other genotypes36, whereas ALK activation is known to retain a mesenchymal phenotype by downregulating E-cadherin37. The gene discussed is ALK; the disease is non-small cell lung carcinoma.